Inactive Instrument

Governance Ampliphi Biosciences Corp Nyse

APHB

US03211P2020

Biotechnology & Medical Research

Executive Committee: Ampliphi Biosciences Corp

Manager

Positions heldSince

Deborah Birx

69 year

Chief Executive Officer

2023-07-10

Peter Hubbard

Chief Operating Officer

David House

41 year

Director of Finance/CFO

2024-08-15

Composition of the Board of Directors: Ampliphi Biosciences Corp

Director

CommitteesSince

Robin Kramer

59 year

Audit Committee Chair

Jules Haimovitz

74 year

Compensation Committee	2018-02-11
Governance Committee	2018-02-11
Nominating Committee	2018-02-11
Audit Committee Chair	2018-02-11
Governance Committee Chair
Nominating Committee Chair

Sarah Schlesinger

65 year

Audit Committee	2018-02-11
Compensation Committee	2020-02-11
Governance Committee Chair	2018-02-11
Nominating Committee Chair	2018-02-11
Governance Committee	2020-02-11
Nominating Committee	2020-02-11

Joseph Patti

61 year

Governance Committee	2019-05-08
Nominating Committee	2019-05-08
Compensation Committee Chair

Odysseas Kostas

50 year

Governance Committee	2023-03-26
Nominating Committee	2023-03-26

Todd Peterson

67 year

Audit Committee

2019-10-09

Deborah Birx

69 year

Director/Board Member

2023-07-10

Former Officers and Directors: Ampliphi Biosciences Corp

Insider

Positions held

SinceUntil

Mina Pastagia

Chief Tech/Sci/R&D Officer

2020-10-25

2024-11-12

Richard Rychlik

Comptroller/Controller/Auditor	2023-09-04	2024-09-29
Director of Finance/CFO	2023-09-04	2024-08-15

Brian Varnum

Director/Board Member	2021-08-01	2023-07-10
Chief Executive Officer	2021-08-01	2023-07-10
President	2019-05-08	2021-08-01

Julianne Averill

Comptroller/Controller/Auditor	2023-05-01	-
Director of Finance/CFO	2023-05-01	2023-09-14

Duane A. Morris

Chief Operating Officer

2019-05-08

2023-04-30

Erin Butler

Chief Administrative Officer	2022-03-31	2022-06-30
Comptroller/Controller/Auditor	2022-06-30	2023-04-30
Director of Finance/CFO	2022-06-30	2023-04-30

Todd R. Patrick

Director/Board Member	2019-05-08	2022-11-15
Chief Executive Officer	2019-05-08	2021-08-01

Steven Martin

Comptroller/Controller/Auditor	-	2022-06-29
Director of Finance/CFO	2019-05-08	2022-06-29
Investor Relations Contact	2019-05-08	2022-06-29

Richard J. Bastiani

Chairman	2019-05-08	2021-06-08
Independent Dir/Board Member	2019-05-08	2021-06-08

H. Parker

Director/Board Member	2019-05-08	2020-12-07
Independent Dir/Board Member	2019-05-08	2020-12-07

Jeremy Curnock-Cook

Director/Board Member	2019-05-08	2020-12-07
Chief Executive Officer	2014-08-31	2015-04-30
Chairman	1995-06-30	-
Independent Dir/Board Member	2019-05-08	2020-12-07

Michael Perry

Director/Board Member	2019-05-08	2020-02-11
Independent Dir/Board Member	2019-05-08	2020-02-11

Richard Bear

Director/Board Member

2019-05-08

2020-02-11

Heather Dale Jones

Chief Tech/Sci/R&D Officer

2019-10-15

Paul Grint

Chief Executive Officer

2019-05-08

Age distribution of managers

Parity Men Women

Male	10
Female	1

Of which Executive Committee

Male	3
Female	0

Of which Directors

Male	6
Female	1

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

ESG MSCI

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-12 - Q4 2024 Earnings Release (Projected)

More about the company